Shares of Mallinckrodt (NYSE: MNK) sank 7.2% as of 3:44 p.m. EST on Monday after dropping as much as 12.8% earlier in the day. The pharmaceutical stock fell on negative tweets from short-seller Citron Research stating that Mallinckrodt had failed in a clinical study of Acthar.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,